Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Complement System01:27

Complement System

2.3K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
2.3K
Neural Regulation01:37

Neural Regulation

39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Amyloid Fibrils03:03

Amyloid Fibrils

9.3K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative phosphoproteomic profiling of CCL5/CCR5 signaling cascade in melanoma cells.

Frontiers in oncology·2026
Same author

Physics-embedded CycleGAN for robust metabolite mapping in short-readout deuterium metabolic imaging.

Magnetic resonance letters·2026
Same author

Hierarchical Semantic Concept Modeling for Generalizable Myocardial Pathology Segmentation on Multisequence CMR Images.

IEEE transactions on neural networks and learning systems·2026
Same author

A joint pilot optimization and channel estimation algorithm based on CBAM-CNN for multipath fading environments in underground coal mines.

Scientific reports·2026
Same author

DecX-Net: a dual-path feature decoupling network with layer-wise feature alignment for subsolid pulmonary nodule segmentation.

Physics in medicine and biology·2026
Same author

Novel Frameshift Variant in SORL1 Gene Identified in a EOAD Family Causes APP Sorting Dysfunction and Endolysosomal Swelling.

Molecular neurobiology·2026

Related Experiment Video

Updated: Jun 9, 2025

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

11.8K

Complement Receptor 1 Is a Potential Extracerebral Factor Promoting α-Synuclein Pathology.

Yunying Yang1, Sichun Chen1, Yan Gao1

  • 1Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.

Molecular Neurobiology
|October 29, 2024
PubMed
Summary

Complement receptor 1 (CR1) promotes alpha-synuclein (α-Syn) pathology in Parkinson's disease. This protein component of the blood system exacerbates α-Syn aggregation, suggesting it as a therapeutic target for synucleinopathies.

Keywords:
AggregationComplement receptor 1PhosphorylationSeedingα-Synuclein

More Related Videos

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation
09:16

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation

Published on: June 26, 2018

7.5K
Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry
07:20

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

Published on: May 19, 2020

7.1K

Related Experiment Videos

Last Updated: Jun 9, 2025

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

11.8K
Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation
09:16

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation

Published on: June 26, 2018

7.5K
Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry
07:20

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

Published on: May 19, 2020

7.1K

Area of Science:

  • Neuroscience
  • Immunology
  • Biochemistry

Background:

  • Parkinson's disease (PD) is characterized by pathological alpha-synuclein (α-Syn) aggregation in the central nervous system (CNS).
  • Pathological α-Syn is also found in peripheral tissues and body fluids of PD patients, with evidence suggesting its transmission from the body to the brain.
  • The factors driving peripheral α-Syn aggregation remain largely unknown.

Purpose of the Study:

  • To investigate the role of peripheral factors in promoting α-Syn pathology.
  • To identify potential therapeutic targets for synucleinopathies by examining extracerebral influences on α-Syn aggregation.

Main Methods:

  • In vitro experiments using the transmembrane domain of complement receptor 1 (CR1-TM) to assess its effect on α-Syn phosphorylation and aggregation.
  • In vivo studies involving intravenous injection of α-Syn fibrils in a mouse model.
  • Co-administration of CR1-TM with α-Syn fibrils to evaluate its impact on induced pathology in the brain.

Main Results:

  • CR1, a peripheral blood system component, was identified as a promoter of α-Syn pathology.
  • CR1-TM exacerbated α-Syn phosphorylation and aggregation in vitro.
  • Intravenous injection of α-Syn fibrils induced brain pathology, which was worsened by co-administered CR1-TM.

Conclusions:

  • Extracerebral factors, specifically CR1, can drive the progression of α-Syn pathology.
  • CR1 represents a potential therapeutic target for treating Parkinson's disease and other synucleinopathies.